Back

Real-world monocentric experience of early impact of SGLT2 inhibitors on NT-proBNP levels in heart failure

19 May 2025 (13:00 - 13:45)
Organised by: Logo
Congress Presentation Part of: Progress in heart failure diverse biomarkers Biomarkers HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Silvia Prosperi

Sapienza University of Rome, Rome (Italy)

6 More presentations in this session

Presentation thumbnail
Novel biomarkers reveal distinct biological phenotypes in heart failure with preserved vs reduced ejection fraction
Associate Professor C. Hage (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Rationale and design of the Biobank of SwedeHF - exploring pathophysiological aspects of heart failure
Associate Professor C. Hage (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Role of biomarkers of cardiovascular remodeling and inflammation in estimation of prognosis in patients with chronic heart failure
Doctor E. Tyleckova (Prague, CZ)
Abstract Slides Video
Presentation thumbnail
Determination of NT-proBNP levels to define heart overload/failure and the effect of triple-inhaled therapy in older COPD patients: a multicenter longitudinal study
Professor R. Sarzani (Ancona, IT)
Abstract Slides Video
Presentation thumbnail
Development and characteristics of immunoturbidimetric NT-proBNP assay based on antibodies targeting glycosylation-free regions of NT-proBNP
Doctor A. Havelka (Moss, NO)
Abstract Slides Video

Access the full session

Session thumbnail
Progress in heart failure diverse biomarkers

The Event

Event poster

Heart Failure 2025

19 May 2025 13:00 CET
You may be interested in
thumbnail
Congress Presentation
Changes in N-terminal pro b-type natriuretic peptide according to SGLT2 inhibitor utilization patterns in patients hospitalized for decompensated heart failure: a prospective cohort study
thumbnail
Congress Presentation
Prognosis and NT-proBNP decrease in heart failure patients from admission to follow up
thumbnail
Congress Presentation
Clinical Implications of NT-proBNP trajectory following Sacubitril/Valsartan initiation

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources